Xenon Pharmaceuticals raises ~$281.6M in underwritten public offering of shares and pre-funded warrants

Xenon Pharmaceuticals Inc.

Net proceeds ~$281.6M from sale of 8,461,542 common shares and 769,230 pre-funded warrants at $32.50 per share/warrant.
Underwriters: J.P. Morgan, Jefferies, BofA Securities, Stifel, and RBC Capital Markets.
Underwriters granted 30-day option to purchase up to an additional 1,384,615 common shares.
Pre-funded warrants exercisable at $0.0001 per share, with 4.99% beneficial ownership limitation (adjustable to 19.99%).
Offering made under existing shelf registration statement (Oct 2021); underwriting agreement dated November 29, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.